Press

NOT YOUR MOM’S PROBIOTIC: GOOGLE-BACKED EVELO TEAMS UP WITH MAYO CLINIC ON MICROBIOME DRUGS
ENDPOINTS NEWS - November 16, 2017

WHY MICROBIOME PLAY EVELO RAISED $50 MILLION TO EXPAND ITS CLINICAL PROGRAM
BioCentury - July 14, 2017

EVELO BIOSCIENCES RAISES $50M IN SERIES B FINANCING
FINSMES - July 13, 2017

FLAGSHIP PIONEERING NURTURES UNIQUE START-UPS UNTIL THEY CAN TAKE WING
Scrip Pharma Intelligence - July 13, 2017

FORGET ANTIMICROBIALS, EVELO JUST RAISED $50M FOR ITS PRO-MICROBIAL APPROACH
MedCity News - July 11, 2017

EVELO BIOSCIENCES GETS $50 MILLION FOR MICROBIAL THERAPEUTICS
WSJ PRO - July 11, 2017

EVELO BIO RAISES $50M ROUND TO BRING MICROBIOME DRUGS INTO TRIALS
XCONOMY - July 11, 2017

WITH FLAGSHIP AND GV PITCHING IN, MICROBIOME STARTUP EVELO NABS $50M
Boston Business Journal - July 11, 2017

EVELO RAISES $50M TO TAKE MONOCLONAL MICROBIALS INTO CLINIC
FierceBiotech - July 11, 2017

BACKED BY GOOGLE (GOOG), EVELO BAGS $50 MILLION AND NAMES SOME INDUSTRY VETS TO THE TEAM
BioSpace - July 11, 2017

AFTER RAISING $100M, GOOGLE-BACKED EVELO LOOKS TO BLAZE A NEW TRAIL WITH MONOCLONAL MICROBIALS
ENDPOINTS NEWS - July 11, 2017

A ONE-BUG DRUG FOR THE IMMUNE SYSTEM? EVELO GETS $50M TO TEST CONCEPT
Timmerman Report - July 11, 2017

THE MICROBIOME AND CANCER: WHAT’S ALL THE FUSS ABOUT?
Cancer Research UK - June 13, 2017

GUT INSTINCT: LEVERAGING THE MICROBIOME AND HUMAN IMMUNE SYSTEM TO DRAMATICALLY TRANSFORM MEDICINE
WuXi AppTec - Innovation That Matters - May 17, 2017

$42M IN, FLAGSHIP STARTUPS MERGE INTO ONE IMMUNO-MICROBIOME PLATFORM WITH MULTIPLE TARGETS
ENDPOINTS NEWS - July 12, 2016

WITH BUGS AS DRUGS, EVELO CEO PLANS IMMUNE, CANCER TRIALS IN 2017
Xconomy - July 12, 2016

MICROBIOME AT THE CHECKPOINT
BioCentury Innovations - December 3, 2015

GUT MICROBES GIVE ANTICANCER TREATMENTS A BOOST
Science - November 5, 2015

THE HOTTEST NEW CANCER DRUGS DEPEND ON GUT MICROBES
The Atlantic - November 5, 2015

FIGHTING CANCER WITH MICROBES, FLAGSHIP BETS ON A $35M STARTUP
Forbes – November 4, 2015

CANCER MICROBIOME PLAY EVELO RAISES $35M 
BioCentury – November 4, 2015

NEW STARTUP TO MAKE BACTERIA-BASED CANCER TREATMENTS
Bioscience Technology – November 5, 2015

FLAGSHIP LAUNCHES ANOTHER MICROBIOME BIOTECH WITH $35M AND A FOCUS ON CANCER
Fierce Biotech – November 4, 2015

FLAGSHIP LAUNCHES EVELO WITH $35M TO EXPLORE MICROBIOME-BASED CANCER TREATMENTS
Bioworld – November 4, 2015

EVELO LAUNCHES WITH $35M TO FIGHT CANCER WITH COCKTAILS OF BACTERIA
Xconomy – November 4, 2015

STARTUP AIMS TO HARNESS THE MICROBIOME TO TREAT CANCER
STAT News – November 4, 2015

NEW STARTUP TO MAKE BACTERIA-BASED CANCER TREATMENTS
Drug Discovery & Development – November 4, 2015

EVELO THERAPEUTICS DEVELOPING MICROBIOME BASED CANCER THERAPIES
Next Big Future – November 4, 2015

FLAGSHIP VENTURES LAUNCHES EVELO THERAPEUTICS WITH $35M
Venture Wire – November 4, 2015

LEVERAGING THE POWER OF THE MICROBIOME – A NEW SOURCE FOR TARGETED CANCER THERAPY
Medcity News – November 4, 2015

THE DAILY STARTUP: 3Q A RECORD FOR NETWORKING, SYSTEMS MANAGEMENT, INVESTMENTS
Wall Street Journal – November 4, 2015

STARTUP EVELO SPRINGS OUT OF FLAGSHIP VENTURELABS WITH $35 MILLION
Biospace – November 4, 2015

FLAGSHIP LAUNCHES ANOTHER MICROBIOME BIOTECH WITH $35M AND A FOCUS ON CANCER
Biotechnika.org – November 5, 2015

EVELO THERAPEUTICS SEEKS TO DISRUPT CANCER ENABLING EFFECTS OF MICROBIOME
Medical Research – November 4, 2015